A targeted combination therapy described in this issue of Nature Medicine may greatly improve outcome in individuals with a fastgrowing blood cancer: T cell acute lymphoblastic leukemia (T-ALL; ref. 1) .
The therapy relies on the combination of a γ-secretase inhibitor with a glucocorticoid, dexamethasone. The γ-secretase inhibitor targets NOTCH1, a transmembrane cell surface receptor that regulates normal T cell development 2 ; activating mutations in the gene encoding NOTCH1 cause more than half of T-ALL cases 3 . Dexamethasone counteracts lethal gut toxicity induced by the γ-secretase inhibitor. The authors outline how the combination therapy induces apoptosis in T-ALL cells-in T-ALL cell lines, primary human T-ALL cells and in xenografts of such T-ALL cell lines in mice-to a much greater extent than either dexamethasone or the inhibitor alone 1 (Fig. 1) .
The approach, if it can be translated to people, might have benefits over current treatment for T-ALL, which accounts for 15% of childhood cases and 25% of adult cases of ALL 4 -a disease that affects approximately 5,000 people each year in the United States. Current multiagent chemotherapy regimens cure about 85% of children with T-ALL but only 50% of adults with T-ALL, and the side effects are substantial 5 . The prognosis of adult patients has remained poor partly as a result of unfavorable genetic features of the leukemia as compared to those in children 5 .
NOTCH1 is a two-chain molecule that, upon interaction of its extracellular domain with ligands of the Delta-Serrate-Lag-2 family, activates the intramembrane presenilin-γ-secretase protease complex that liberates the intracellular domain of NOTCH1, ICN1, from the lipid bilayer. After translocation to the nucleus, the ICN1 associates with the transcription factor CSL 6 and activates the transcription of a set of target genes including the proliferation-promoting oncogene MYC. Although MYC upregulation contributes to NOTCH1-induced cellular transformation, experimental evidence suggests that the participation of additional responder genes is required in this process 5 . The introduction of activated NOTCH1 alleles into mouse bone marrow leads to the development of T-ALL 7 . This finding suggests that NOTCH1 activation is also an aspect of the human T-ALL disease process. This hypothesis is further supported by the observation that activated NOTCH1 is essential for maintaining the transformed state of the human malignant cells 8 .
Real et al. 1 started their investigation by testing the hypothesis that T-ALL cell lines with activated NOTCH1 are resistant to glucocorticoid-induced apoptosis owing to their aberrant NOTCH1 signaling. Indeed, the cells showed minimal loss of viability after treatment with dexamethasone or the γ-secretase inhibitor alone but were highly sensitive to the combined treatment. The authors show that the direct target of activated NOTCH1, the inhibitory transcription factor HES1, binds the promoter of the gene NR3C1, which encodes the glucocorticoid receptor, thereby inhibiting its expression. Treatment with inhibitor and dexamethasone enhanced NR3C1 expression and activity, which upregulates the expression of its known target, the proapoptotic gene BCL2L11, resulting in apoptosis ( Fig. 1) .
How does dexamethasone reverse inhibitorinduced intestinal toxicity in mice? γ-secretase inhibitors cause severe intestinal secretory metaplasia as a result of a marked increase in goblet cell differentiation 9 and arrested cell proliferation in the intestinal crypts. The tumor suppressor gene Klf4, which encodes a Kruppel-like transcription factor, normally regulates goblet cell differentiation 10 . Again, the authors show that increased HES1 expression in inhibitortreated mice suppressed Klf4 expression directly work may provide new ways for treating that condition.
The new findings will initiate a flurry of research activity to further validate the combination therapy in additional preclinical studies 1 . Provided that the outcome will be positive, the approach will be ready to move into phase 1 trials.
whether the combination therapy with dexamethasone is as safe in humans as it seems to be in mice. No doubt it will take time to determine the optimal safe dosage for treatment; Real et al. report that in a small number of their mice, the combined treatment had to be stopped owing to excessive weight loss 1 . The combination treatment also increased lymphoid atrophy in the thymus and spleen, thereby potentially diminishing normal immunity.
Despite the promise of this approach for NOTCH1-activated T-ALL, not all people with this condition would be expected to respond. Eight percent of T-ALL samples harbor mutations in or show homozygous deletion of FBW7, a gene that encodes a ubiquitin ligase responsible for NOTCH1 ICN1 turnover. T-ALL cell lines carrying such mutations are resistant to treatment with γ-secretase inhibitors 13 .
The findings of Real et al. 1 may have broader implications, as NOTCH1 signaling is involved in many cancers 14 . By inference, the combination therapy might also be beneficial for solid tumors with aberrant NOTCH1 signaling. Likewise, γ-secretase inhibitors inhibit the production of amyloidogenic β-amyloid peptides involved in Alzheimer's disease, and this by increasing the binding of HES1 to the Klf4 promoter 1 . Subsequent transcription profiling revealed that the intestines of mice treated with the inhibitor and dexamethasone expressed more Ccnd2, a cell cycle regulator, than did those of mice treated with the inhibitor alone. The authors provide evidence that the dexamethasone-induced expression of Ccnd2, at least in part, protects the mice from inhibitor-induced goblet cell metaplasia, although its observed effect on Klf4 downregulation is indirect 1 .
The known toxicity of dexamethasone treatment includes osteopenia, hypertension and muscle atrophy; however, the potential effects of long-term inhibition of γ-secretase remain unknown. The enzyme γ-secretase targets more than 30 physiologically important transmembrane proteins, including the amyloid precursor protein involved in Alzheimer's disease 11 . Given that there are at least six different γ-secretase complexes in humans, subtype-specific inhibitors might be developed that have less broad side effects 12 .
Clinical trials of γ-secretase inhibitors have been hindered by the considerable gastrointestinal problems experienced by the participants 12 . Therefore, it will be necessary to determine Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants. By two years of age, more than 90% of children have been infected at least once with this virus. RSV infections typically cause mild illness; however, severe respiratory disease can occur and is associated with symptoms such as bronchiolitis and wheezing. RSV infection is also common in the elderly, in whom it can be deadly. Despite the enormous impact of RSV on human health, the design of a safe and successful vaccine has eluded researchers.
Fixing a failed vaccine
During the 1960s, researchers thought they had a vaccine. But they were wrong-the experimental, formalin-inactivated RSV vaccine administered to children not only failed protect them but also exacerbated their illness in response to natural RSV exposure. Many of the children developed bronchiolitis and pneumonia so severe that it required hospitalization, and, unfortunately, two of the vaccinated children died 1 .
The formalin-inactivated RSV vaccine did elicit antibodies-but these were not neutralizing, meaning that they did not inactivate the virus. High titers of RSV were recovered from the lungs of the two children that died, demonstrating the ineffectiveness of the vaccine in eliciting a protective immune response 1 .
In this issue of Nature Medicine, Delgado et al. 2 provide insight into the failure of the formalin-inactivated RSV vaccine. They report that inactivated forms of RSV do not sufficiently activate various pattern recognition receptors, molecules important for the recognition of pathogens by immune cells and expressed by several cell types including B cells, the cells that produce antibodies. As a result of this poor activation, B cells produce only low-avidity antibodies that poorly recognize the virus. Because the vaccine elicited such poor antibodies, it failed to inhibit virus replication and resulted in enhanced disease, probably caused by the host immune response.
The vaccine-enhanced disease exhibited by the children during the 1960s vaccine trial can be recapitulated in mice. Early studies in the mouse model clearly established that the host immune response contributes to the development of RSV vaccine-enhanced disease. As in people, immunization with formalininactivated RSV results in the production of non-neutralizing RSV-specific antibodies 3 . After RSV challenge, these non-neutralizing antibodies cause the formation of immune
